High-dose corticosteroids in patients with the adult respiratory distress syndrome. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA (1987) N Engl J Med 317: 1565-70 Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. Robertson RM, Robertson D, Roberts LJ, Maas RL, FitzGerald GA, Friesinger GC, Oates JA (1981) N Engl J Med 304: 998-1003 Cancer pharmacogenomics: strategies and challenges. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ (2013) Nat Rev Genet 14: 23-34 Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Biaggioni I, Robertson D (1987) Lancet 2: 1170-2 HIV prevention in women: next steps. Vermund SH, Van Damme L (2011) Science 331: 284 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Coussens LM, Fingleton B, Matrisian LM (2002) Science 295: 2387-92 Defining sepsis. Knaus WA, Harrell FE, Wagner DP (1994) JAMA 272: 1901 The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. Knaus WA, Harrell FE, Fisher CJ, Wagner DP, Opal SM, Sadoff JC, Draper EA, Walawander CA, Conboy K, Grasela TH (1993) JAMA 270: 1233-41 Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Arteaga CL, Baselga J (2004) Cancer Cell 5: 525-31 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology (2011) J Clin Oncol 29: 3825-31 Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Moslehi JJ, Deininger M (2015) J Clin Oncol 33: 4210-8 Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) J Clin Oncol 27: 5660-9 Authorship and industry financial relationships: the tie that binds. Johnson DH, Horn L (2010) J Clin Oncol 28: 1281-3 American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G (2011) J Clin Oncol 29: 2121-7 American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE (2014) J Clin Oncol 32: 1277-80 Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) J Clin Oncol 29: 3450-6 Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. Rao G, Crispens M, Rothenberg ML (2007) J Clin Oncol 25: 2867-72 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Miller TW, Balko JM, Arteaga CL (2011) J Clin Oncol 29: 4452-61 EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. Arteaga CL (2003) J Clin Oncol 21: 289s-291s Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Pao W, Miller VA (2005) J Clin Oncol 23: 2556-68 Interpreting P values in pharmacogenetic studies: a call for process and perspective. Maitland ML, Ratain MJ, Cox NJ (2007) J Clin Oncol 25: 4513-5 Matrix metalloproteinases: biologic activity and clinical implications. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) J Clin Oncol 18: 1135-49 Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim H, Wahl RL (2014) J Clin Oncol 32: 2115-6 Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? Rothenberg ML, Berlin JD (2003) J Clin Oncol 21: 3716-7 Past and future of pancreas cancer: are we ready to move forward together? Merchant N, Berlin J (2008) J Clin Oncol 26: 3478-80 High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Hainsworth JD, Burnett LS, Jones HW, Grosh WW, Johnson DH, Greco FA (1990) J Clin Oncol 8: 502-8 Ethics in oncology: consulting for the investment industry. Berlin J, Bruinooge SS, Tannock IF (2007) J Clin Oncol 25: 444-6 Problems and advantages of an observational data base approach to evaluating the effect of therapy on outcome. Rosati RA, Lee KL, Califf RM, Pryor DB, Harrell FE (1982) Circulation 65: 27-32 Clopidogrel and the concept of high-risk pharmacokinetics. Roden DM, Stein CM (2009) Circulation 119: 2127-30 Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White C, Wang TJ, Gardner JP, Cao X, Benjamin EJ, Levy D, Aviv A (2008) Circulation 117: 1138-44 Current perspectives on statins. Maron DJ, Fazio S, Linton MF (2000) Circulation 101: 207-13 Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. Burfeind WR, Glower DD, Wechsler AS, Tuttle RH, Shaw LK, Harrell FE, Rankin JS (2004) Circulation 110: II27-35 Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. Califf RM, Hlatky MA, Mark DB, Lee KL, Harrell FE, Rosati RA, Pryor DB (1985) Circulation 72: V136-44 Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Berlin J, Benson AB (2010) Nat Rev Clin Oncol 7: 135-7 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Nat Rev Clin Oncol 13: 674-690 Prostate cancer and the Will Rogers phenomenon. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J (2005) J Natl Cancer Inst 97: 1248-53
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.